Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)

INCLUSION CRITERIA

Procurement Inclusion Criteria:

Referred patients will initially be consented for procurement of blood for generation of the transduced ATL. Eligibility criteria at this stage include:

* Diagnosis of recurrent CD30+ HL or CD30+ NHL, or newly diagnosed patients unable to receive or complete standard therapy OR diagnosis of relapsed/refractory CD30+ HL or CD30+ NHL with a treatment plan that will include high dose therapy and stem cell transplantation
* CD30 positive tumor (result can be pending at this time)
* Hgb \> 8.0
* Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.
* Karnofsky or Lansky score greater than 60%

Procurement Exclusion Criteria

\- Active infection with HIV, HTLV, HBV, HCV (can be pending at this time).

Treatment Inclusion Criteria:

Diagnosis - CD30+ HL or CD30+ NHL:

1. During the Dose Escalation Phase: only adult patients with active disease failing standard therapy
2. After Dose Escalation: any patient (children or adults) newly diagnosed, unable to receive or complete standard therapy OR diagnosis of relapsed/refractory CD30+ HL or CD30+ NHL with a treatment plan that will include high dose therapy and autologous stem cell transplantation. (During dose escalation: only adult patients (age 18 and older; After Dose Escalation: any patient (children ages 0-17 or adults)

   * CD30 positive tumor
   * Bilirubin 1.5 times or less than upper limit of normal.
   * AST 3 times or less than upper limit of normal.
   * Serum creatinine 1.5 times or less than upper limit of normal.
   * Pulse oximetry of \> 90% on room air
   * Karnofsky or Lansky score of \> 60%.
   * Available autologous T cells with 15% or more expression of CD30CAR determined by flow-cytometry.
   * Recovered from acute toxic effects of all prior chemotherapy at least one week and 30 days from prior chemotherapy before entering this study
   * Adequate pulmonary function with FEV1, FVC and DLCO greater than or equal to 50% of expected corrected for hemoglobin.
   * Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom.
   * Patients or legal guardians must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effects. Patients or their guardians will be given a copy of the consent form.

EXCLUSION CRITERIA:

Procurement Exclusion Criteria:

\- Active infection with HIV, HTLV, HBV, HCV (can be pending at this time).

Treatment Exclusion Criteria:

* Currently receiving any investigational agents or received any tumor vaccines within the previous six weeks.
* Received anti-CD30 antibody-based therapy within the previous 4 weeks.
* History of hypersensitivity reactions to murine protein-containing products.
* Pregnant or lactating.
* Tumor in a location where enlargement could cause airway obstruction.
* Current use of systemic corticosteroids.